Key Highlights

  • Senseonics (NASDAQ:SENS) ended Tuesday, November 10, 2026 at USD 12.36, a 26.12% advance from a calculated prior close of USD 9.80, or USD 2.56 a share, ranking among the day's biggest US gainers.
  • Third-quarter 2026 revenue, released on November 9, 2026, was USD 19.6 million, about 140% above USD 8.1 million a year earlier, with gross Margin near 62% versus 43%.
  • Full-year 2026 Revenue guidance was lifted to USD 68 million to USD 70 million from USD 62 million to USD 66 million, even as the quarterly net loss widened to USD 32.7 million.
  • Trading reached 2.12 million shares, a relative Volume of 2.70, worth about USD 26.20 million at the close (calculated), alongside a Market Value of USD 653.52 million and trailing EPS of USD -2.28.

What Drove Senseonics on November 10 (+26.12%)

Senseonics, maker of the Eversense implantable continuous glucose monitoring system, closed the regular session at USD 12.36, a 26.12% gain. Simple arithmetic on the published change yields a calculated prior close of USD 9.80 for Monday, November 9, 2026. The shares had been indicated 13.27% higher at USD 11.10 in pre-market trading, so the regular session roughly doubled that early gain. Volume of 2.12 million shares at a relative volume of 2.70 means activity ran near 2.7 times the recent average. The company issued third-quarter results on November 9, 2026: revenue of USD 19.6 million versus USD 8.1 million, US revenue of USD 16.8 million versus USD 6.4 million, and revenue outside the US of USD 2.8 million versus USD 1.7 million.

The Rationale: Results and Higher Guidance

The catalyst identified is the results release and guidance. Gross Profit was USD 12.1 million, a margin near 62%, and management lifted 2026 revenue guidance to USD 68 million to USD 70 million from USD 62 million to USD 66 million, which implies growth of roughly 93% to 98%. The gross margin outlook moved above 60%. As general context, higher guidance resets analyst models and may draw in buyers. Costs climbed too: selling, general and administrative expense reached USD 32.3 million versus USD 15.3 million, and Research and Development reached USD 11.7 million versus USD 7.8 million, leaving a net loss of USD 32.7 million, or USD 0.50 per share, versus USD 19.5 million, or USD 0.43. The company is also pushing Gemini through clinical trials.

Valuation, Liquidity and Risk Factors for Senseonics

The screener snapshot lists no P/E, trailing diluted EPS of USD -2.28, EPS growth of -11.42% and a dividend Yield of 0.00%. The release reported 54,775,503 shares outstanding at September 30, 2026, which at USD 12.36 yields a market value near USD 677.0 million (calculated), above the snapshot's USD 653.52 million, a difference that hints at a different share basis. On the guidance midpoint of USD 69 million, that is about 9.8 times revenue (calculated). Cash and short-term investments were USD 126.6 million against USD 55.0 million of principal under the Hercules facility, a calculated net cash of USD 71.6 million. Ongoing losses may call for financing and dilution. A 26.12% one-day gain can reverse, and nothing here suggests the move will continue.

Where Things Stand

Senseonics (NASDAQ:SENS) gained 26.12% to USD 12.36 on November 10, 2026 as investors responded to the November 9 release showing USD 19.6 million of third-quarter revenue, a gross margin near 62% and 2026 guidance lifted to USD 68 million to USD 70 million. The USD 32.7 million net loss, USD 55.0 million of Debt and trading at 2.70 times typical volume are the offsetting risks.